Darzalex (Johnson & Johnson) is expected to face US biosimilar competition from 2029. Core US patents expire 2029. Formulation patents on subcutaneous Darzalex Faspro run longer.
Darzalex's US exclusivity date is based on patent-expiry estimate. It is estimated from patent expiry rather than a fixed entry date, so it may move as patents are challenged or extended. It is a biologic, so copies are biosimilars. Biosimilars are harder to make and usually erode sales more gradually than generics.
Darzalex is 15% of Johnson & Johnson's 2025 revenue ($14.3B of $94.2B). With Stelara, the drugs tracked here add up to 22% of Johnson & Johnson's revenue losing US exclusivity by 2029. Total includes MedTech.
Bars show each company's tracked drugs as a share of its total 2025 revenue. Darzalex is highlighted.